Healthcare Industry News: Takeda Pharmaceutical
News Release - December 15, 2010
Aperio Continues Leadership in Digital PathologyMore than 700 Systems in over 30 Countries Enables Improved Patient Care Worldwide
VISTA, Calif.--(Healthcare Sales & Marketing Network)-- Aperio, the global leader in providing digital pathology solutions to improve patient care, today announced that the company is seeing growing global demand for its patented digital pathology system, including its ScanScope® suite of scanners and Spectrum™ information management (PACS) software, leading to continued market expansion.
Aperio boasts a global installed base of more than 700 systems in over 30 countries, including two-thirds of the top 15 rated U.S. hospitals, leading reference laboratories, the 13 largest pharmaceutical companies and a multitude of biotechnology and government organizations.
“Our sustained market leadership and expansion is an exciting milestone for us, and underscores our commitment and ability to meet the varying needs of pathologists around the world,” stated Dirk G. Soenksen, CEO of Aperio. “Our customers rely on our digital pathology systems and services to provide a more adaptive and integrated environment to enhance the efficiency and accuracy of anatomic pathology, resulting in lower costs and improved patient care.”
As digital pathology moves closer to the critical path among clinical organizations, hospitals and academic medical centers are using Aperio’s systems to improve secondary and intra-operative consultations, tumor boards and quality assurance over reads. Intermountain Healthcare, Memorial Sloan-Kettering Cancer Center and Yale University School of Medicine have recently made investments in this advanced technology, bringing the number of systems in healthcare organizations to nearly 500.
Digital pathology is also transforming global pharmaceutical research by enabling data sharing to integrate geographically distributed pathology labs around the world, eliminating geography barriers, reducing subjectivity and improving pathology.
Aperio serves a number of life sciences companies that are leading pharmaceutical research in the area of personalized medicine through biomarker discovery. Among them are Novartis, Pfizer, Sanofi-Aventis, Takeda Pharmaceutical and Astellas Pharma Inc., Japan’s second largest pharmaceutical company and ranked within the top 20 in the global market.
Aperio has an established global network of regional distributors providing local sales and support to meet the increased demand for digital pathology systems, and currently maintains its headquarters in the United States with offices in Australia, Canada, Japan and the United Kingdom.
Aperio continues to forge new advancements in digital pathology with an intellectual property portfolio comprising more than 80 issued and pending patents world-wide.
Aperio is the leading provider of digital pathology solutions in hospitals, reference labs, and pharmaceutical and research institutions across the world. Today, our affordable and complete product portfolio improves patient care by enhancing quality assurance, delivering more efficient workflows, facilitating access to new and more targeted therapies, and improving pathologists’ skills via lifelong education. Our comprehensive product line features our ScanScope® scanners, Spectrum™ image management (PACS) software, SecondSlide® slide sharing service for pathology, and image analysis tools and services. Aperio’s products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications. For clearance updates and more information please visit www.aperio.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.